Nordic Nanovector ASA: Proposal from the Nomination Committee to the Annual General Meeting 19 May 2016

Oslo, Norway, 13 May 2016

Reference is made to the notice published on 28 April 2016 regarding the Annual General Meeting in Nordic Nanovector ASA (the "Company") (OSE: NANO) to be held on 19 May 2016  at 10:00 am (CEST) at Thon Hotel Vika Atrium in Munkedamsveien 45 in Oslo.

The proposal by the Nomination Committee referred to in items 7, 8, 9 and 10 of the notice is attached and available on the Company's website www.nordicnanovector.com.

Due to the delayed publication of the proposal from the Nomination Committee, the Company has decided that the deadline for submitting the notice of attendance to the Annual General Meeting and/or the power of attorney and prior voting is prolonged from 15 May 2016 at 16.00 (CEST) to 18 May 2016 at 12:00 (CEST).

For further information, please contact:

Tone Kvåle, Chief Financial Officer

Phone: +47 91 51 95 76

E-mail: tkvale@nordicnanovector.com

About Nordic Nanovector:

Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company's lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionclide-Conjugates (ARC) designed to improve upon a complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over USD 12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulator submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation to Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com.

This information is subject to duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Tags:

About Us

About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Subscribe

Documents & Links